Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Detection of BRAF mutations in the tumour and serum of patients enrolled in the AZD6244 (ARRY-142886) advanced melanoma phase II study.

British journal of cancer - 17 Nov 2009

Board R E, Ellison G, Orr M C M, Kemsley K R, McWalter G, Blockley L Y, Dearden S P, Morris C, Ranson M, Cantarini M V, Dive C, Hughes A

Abstract excerpt

BACKGROUND: This study investigated the potential clinical utility of circulating free DNA (cfDNA) as a source of BRAF mutation detection in patients enrolled into a phase II study of AZD6244, a specific MEK1/2 inhibitor, in patients with advanced melanoma. METHODS: BRAF mutations were detected u...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Benzimidazoles
Share to Disease-Free Survival

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA, Neoplasm

Share to HT29 Cells

Share to Melanoma

Share to Proto-Oncogene Proteins B-raf

Share to Skin Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 19861964
DOI: 10.1038/sj.bjc.6605371
PMCID: PMC2778539

Genes

BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-19861964-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Detection of BRAF mutations in the tumour and serum of patients enrolled in the AZD6244 (ARRY-142886) advanced melanoma phase II study.PMID 19861964Read ↗

BRAF mutation analysis in circulating free tumor DNA of melanoma patients treated with BRAF inhibitors.Semantic proximity Read ↗

Correlation of BRAF Mutation Status in Circulating-Free DNA and Tumor and Association with Clinical Outcome across Four BRAFi and MEKi Clinical Trials.Semantic proximity Read ↗

<i>BRAF</i> Mutation Testing in Cell-Free DNA from the Plasma of Patients with Advanced Cancers Using a Rapid, Automated Molecular Diagnostics SystemSemantic proximity Read ↗

Circulating tumor DNA as a marker of treatment response in BRAF V600E mutated non-melanoma solid tumorsSemantic proximity Read ↗

cfDNA analysis from blood in melanoma.Semantic proximity Read ↗

Quantitative assessment of BRAF V600 mutant circulating cell-free tumor DNA as a tool for therapeutic monitoring in metastatic melanoma patients treated with BRAF/MEK inhibitors.Semantic proximity Read ↗

Microarray-based analysis of the BRAF V600 mutations in circulating tumor DNA in melanoma patients.Semantic proximity Read ↗

Circulating tumour DNA in patients with advanced melanoma treated with dabrafenib or dabrafenib plus trametinib: a clinical validation studySemantic proximity Read ↗

Quantitative cell-free circulating BRAFV600E mutation analysis by use of droplet digital PCR in the follow-up of patients with melanoma being treated with BRAF inhibitors.Semantic proximity Read ↗

Reliability of BRAF mutation detection using plasma sample: A systematic review and meta-analysisSemantic proximity Read ↗

Sensitivity of plasma BRAFmutant and NRASmutant cell-free DNA assays to detect metastatic melanoma in patients with low RECIST scores and non-RECIST disease progression.Semantic proximity Read ↗

Clinical significance of <scp>BRAF</scp> mutation status in circulating tumor <scp>DNA</scp> of metastatic melanoma patients at baselineSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.